Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells

Myeloid-derived suppressor cells (MDSC) potently repress antitumor immunity. The amount of MDSC in the blood of melanoma patients declines in response to vemurafenib, an inhibitor of oncogenic BRAF signaling that abrogates the ability of malignant cells to induce MDSC. This suggests that vemurafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Schilling, Bastian, Paschen, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805652/
https://www.ncbi.nlm.nih.gov/pubmed/24167759
http://dx.doi.org/10.4161/onci.25218
_version_ 1782477896031404032
author Schilling, Bastian
Paschen, Annette
author_facet Schilling, Bastian
Paschen, Annette
author_sort Schilling, Bastian
collection PubMed
description Myeloid-derived suppressor cells (MDSC) potently repress antitumor immunity. The amount of MDSC in the blood of melanoma patients declines in response to vemurafenib, an inhibitor of oncogenic BRAF signaling that abrogates the ability of malignant cells to induce MDSC. This suggests that vemurafenib may be used in combination with various immunotherapeutic agents for the induction of long-lasting tumor regression.
format Online
Article
Text
id pubmed-3805652
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38056522013-10-28 Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells Schilling, Bastian Paschen, Annette Oncoimmunology Author's View Myeloid-derived suppressor cells (MDSC) potently repress antitumor immunity. The amount of MDSC in the blood of melanoma patients declines in response to vemurafenib, an inhibitor of oncogenic BRAF signaling that abrogates the ability of malignant cells to induce MDSC. This suggests that vemurafenib may be used in combination with various immunotherapeutic agents for the induction of long-lasting tumor regression. Landes Bioscience 2013-08-01 2013-06-10 /pmc/articles/PMC3805652/ /pubmed/24167759 http://dx.doi.org/10.4161/onci.25218 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Schilling, Bastian
Paschen, Annette
Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
title Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
title_full Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
title_fullStr Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
title_full_unstemmed Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
title_short Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
title_sort immunological consequences of selective braf inhibitors in malignant melanoma: neutralization of myeloid-derived suppressor cells
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805652/
https://www.ncbi.nlm.nih.gov/pubmed/24167759
http://dx.doi.org/10.4161/onci.25218
work_keys_str_mv AT schillingbastian immunologicalconsequencesofselectivebrafinhibitorsinmalignantmelanomaneutralizationofmyeloidderivedsuppressorcells
AT paschenannette immunologicalconsequencesofselectivebrafinhibitorsinmalignantmelanomaneutralizationofmyeloidderivedsuppressorcells

Ejemplares similares